A Study Of ECG-Based Artificial Intelligence Software-as-Medical Devices

Overview

About this study

The primary purpose of this study is to validate the sensitivity and specificity of Anumana ECG-AI software-as-a-medical devices to detect a number of clinical conditions: 1) Regional wall motion abnormalities 2) Hypertension and related cardiac structural changes 3) Left Ventricular Systolic Dysfunction 4) Diastolic Dysfunction 5) Incident/Latent Atrial Fibrillation

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Must meet any one of the following criteria and Age ≥ 18:

  • (ECG-AI CAD) Has an ECG within 30 days prior to or on the same day as an echocardiographic assessment of 16/17 segments regional wall motion abnormalities (target N = 5,000 patients per site)

  • (ECG-AI HTN-HHD)

    • HTN: In patients receiving continuous primary care, have ECGs within ±1 year of subsequent primary care BP recordings. (target N = 7,000 patients per site)

    • HHD: Has an ECG within 30 days prior to or on the same day as echocardiogram that contains the following measurements (target N = 5,000 patients per site):

      • Left ventricular mass index (LVMI)

      • Left atrial volume index (LAVI)

  • (ECG-AI DD) Has an ECG within 30 days prior to or on the same day as an echocardiogram that contains all six of the following measurements (target N = 5,000 patients per site):

    • Septal e’ velocity

    • E/e’

    • Tricuspid regurgitation velocity

    • Left atrial volume index

    • Mitral E/A ratio

    • Left ventricular ejection fraction

  • ECG-AI LEF V2) Has an ECG within 30 days prior to or on the same day as an echocardiogram that contains the following measurements (target N = 6,000 patients per site):

    • Left ventricular ejection fraction by biplane Simpson’s method (LVEF)

  • (ECG-AI IAF) In patients receiving continuous primary care, have a nonAF ECG that has a follow up primary care visit 3 years after the ECG under consideration (target N = 10,000 per site)

Exclusion Criteria:

  • Subjects who meet any of the following exclusion criteria will not be included in the study:

    • No subject consent obtained, or no IRB waiver granted.

    • Subjects who only have ECGs with signals shorter than 10 seconds or that are not interpretable.

    • Additional exclusion criteria for each SaMD studied will be applied post-data collection, using deidentified clinical data, by the analysis team. These are detailed in the statistical analysis plans for each algorithm.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 10/14/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Konstantinos Siontis

Open for enrollment

Contact information:

Konstantinos Siontis

siontis.konstantinos@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20597277

Mayo Clinic Footer